A Randomised, Assessor-blind, Placebo and Active Controlled, Parallel Group Study to Assess the Phototoxic Potential of Faldaprevir (Administered Orally, Once Daily) for 6 Days in Healthy Male and Female Subjects
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2014
At a glance
- Drugs Faldaprevir (Primary) ; Ciprofloxacin
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 24 Jun 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 30 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 21 Apr 2014 New trial record